ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2026
Unmet needs in functional neurological disorder related to digital healthcare.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional neurological disorder (FND) is a common yet historically neglected condition that presents major unmet needs across diagnosis, treatment and health service delivery. This article examines how digital healthcare could address gaps in several areas: (i) using large biobank and clinic datasets to reveal epidemiology, comorbidity, mechanisms, economic burden and possibly treatment effects; (ii) augmenting complex and time-consuming assessment processes that currently exceed clinical capacity with artificial intelligence; (iii) using digital tools to improve diagnostic precision-for example through automated tremor analysis, quantification of functional motor signs and speech recognition; (iv) improving self-management and access to therapy via online tools and telehealth programmes; (v) improving outcome measurement and existing therapy using wearables and telehealth; and (vi) new therapies such as AI-assisted therapies, biofeedback and virtual or augmented reality interventions. Finally, I discuss the risks of depersonalization, privacy breaches, therapeutic substitution, digital dependence and digital exclusion. In addition, positive therapist effects-variability in outcomes driven by the clinician rather than the intervention-remain difficult to replicate digitally. The challenge for clinicians and researchers is to ensure that technological advances humanize rather than mechanize care, harnessing digital tools to extend expertise, consistency and accessibility without eroding the therapeutic relationship at the heart of effective FND treatment. This article is part of the discussion meeting issue 'Digital healthcare for the management of functional neurological disorders'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.